ImmunityBio (IBRX) Change in Receivables (2014 - 2026)
ImmunityBio (IBRX) posted quarterly Change in Receivables of $700000.0 for Q1 2026, down 95.23% year-over-year from $14.7 million in Q1 2025, and down 93.37% quarter-over-quarter from $10.6 million in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Change in Receivables (2014 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Change in Receivables for 5 consecutive years, with $700000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 95.23% year-over-year to $700000.0; the TTM figure through Mar 2026 stood at $26.2 million (up 54.1% YoY), while the FY2025 annual figure was $40.2 million, up 1603.86% from the prior year.
- Change in Receivables retreated to $700000.0 in Q1 2026 per IBRX's latest filing, from $10.6 million in the prior quarter.
- Across five years, Change in Receivables topped out at $14.7 million in Q1 2025 and bottomed at -$1.8 million in Q4 2024.
- Historically, Change in Receivables has averaged $5.4 million across 3 years, with a median of $4.1 million in 2024.
- Annual changes were most pronounced in 2025 — Change in Receivables surged 681.54% — and 2026, when it slumped 95.23%.
- ImmunityBio's Change in Receivables stood at -$1.8 million in 2024, then soared by 681.54% to $10.6 million in 2025, then tumbled by 93.37% to $700000.0 in 2026.
- Business Quant data shows IBRX's Change in Receivables at $700000.0 in Q1 2026, $10.6 million in Q4 2025, and $9.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | ImmunityBio | 8.51 Bn | 8.15 Bn | 50.94 Mn | 10.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.20 Mn |
| Mar 31, 2026 | 700,000.00 |
| Dec 31, 2025 | 10.56 Mn |
| Sep 30, 2025 | 9.89 Mn |
| Jun 30, 2025 | 5.10 Mn |
| Mar 31, 2025 | 14.67 Mn |
| Dec 31, 2024 | -1.82 Mn |
| Sep 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Sep 30, 2015 | 25,000.00 |
| Jun 30, 2015 | 5,000.00 |
| Mar 31, 2015 | -105,000.00 |
| Dec 31, 2014 | 56,000.00 |
| Sep 30, 2014 | 39,000.00 |